Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Trial Details

NCT ID
NCT07102901
Phase
PHASE2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • SHR2554 Tablets
  • SHR-A1811 Injection
  • SHR-A1904 Injection
  • SHR-1701 Injection
Locations (sample)
  • Harbin, Heilongjiang, China|45.75,126.65
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • At least 18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.
  • Has at least 1 measurable lesion based on investigator imaging assessment (computed tomography or magnetic resonance imaging) using RECIST v1.1 at …
  • Is willing to provide an adequate tumor sample.
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at Screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →